American Society of Clinical Oncology Statement: Toward Individualized Care for Patients With Advanced Cancer
Indiana University-Purdue University Indianapolis, Indianapolis, Indiana, United States Journal of Clinical Oncology
(Impact Factor: 18.43).
02/2011; 29(6):755-60. DOI: 10.1200/JCO.2010.33.1744
Patients with advanced incurable cancer face complex physical, psychological, social, and spiritual consequences of disease and its treatment. Care for these patients should include an individualized assessment of the patient's needs, goals, and preferences throughout the course of illness. Consideration of disease-directed therapy, symptom management, and attention to quality of life are important aspects of quality cancer care. However, emerging evidence suggests that, too often, realistic conversations about prognosis, the potential benefits and limitations of disease-directed therapy, and the potential role of palliative care, either in conjunction with or as an alternative to disease-directed therapy, occur late in the course of illness or not at all. This article addresses the American Society of Clinical Oncology's (ASCO's) vision for improved communication with and decision making for patients with advanced cancer. This statement advocates an individualized approach to discussing and providing disease-directed and supportive care options for patients with advanced cancer throughout the continuum of care. Building on ASCO's prior statements on end-of-life care (1998) and palliative care (2009), this article reviews the evidence for improved patient care in advanced cancer when patients' individual goals and preferences for care are discussed. It outlines the goals for individualized care, barriers that currently limit realization of this vision, and possible strategies to overcome these barriers that can improve care consistent with the goals of our patients and evidence-based medical practice.
Available from: synapse.koreamed.org
- ")에서 항암제 투여 및 암환자 간호와 관련된 실무지침을 개 정하고 제공하여(Azzoli et al., 2011; Peppercorn et al., 2011 "
[Show abstract] [Hide abstract]
This study was done to develop tool to evaluate the core competencies regarding nursing cancer patients on chemotherapy, and to verify the reliability and efficacy of the developed tool.
A tool to evaluate the core competencies was developed from a preliminary tool consisting of 112 items verified by expert groups. The adequacy of the preliminary tool was analyzed and refined to the final evaluation tool containing 76 items in 8 core competencies and 18 specific competencies. The evaluation tool is in the form of a self-report, and each item is evaluated according to a 3-point scale. From September 22 to October 14, 2011, 349 survey responses were analyzed using SPSS 20.0 and the WINSTEPS program that employs the Rasch model.
Results indicated that there were no inappropriate items and the items had low levels of difficulty in comparison with the knowledge levels of the study participants. The results of factor analysis yielded 18 factors, and the reliability of the tools was very high with Cronbach's α=.97.
The results of this study can be used for training and evaluation of core competencies for nursing cancer patients, and for standardizing nursing practices associated with chemotherapy.
Journal of Korean Academy of Nursing 10/2012; 42(5):632-643. DOI:10.4040/jkan.2012.42.5.632 · 0.38 Impact Factor
- "Creating opportunities for patients to discuss about endof-life issues is crucial (Emanuel et al. 2004; Barclay & Maher 2010; Emanuel & Scandrett 2010; Peppercorn et al. 2011) and can provide helpful information for their care. The results of our study on a sample of 88 patients aware of their terminal condition and willing to discuss it confirm that patients' preferences are varied and can differ from conventional expectations of end-of-life issues. "
[Show abstract] [Hide abstract]
ABSTRACT: The aim of the present study is to describe end-of-life preferences of advanced cancer patients willing to talk about death issues. Eighty-eight advanced cancer patients were interviewed through End of Life Preferences Interview (ELPI), a 23-item interview covering a wide range of end-of-life care issues. Most interviewed subjects were home care patients and their median survival after ELPI administration was 69 days. In total, 100% of responders expressed the will to receive some kind of information on the disease process and/or the treatments proposed. Approximately 77% declared to be willing to talk about what it is important at the end of life in case of worsening of their conditions and 31% prefer to be left alone in difficult moments. Approximately 67% choose home as the preferred place of death and 63% think it is preferable to die in a state of unconsciousness induced by drugs. About half of responders declare to believe in any kind of life after death and 40% consider very important to find any meaning at the end of life. ELPI can be a useful instrument to adapt the model of care to the specific needs and values of each patient.
European Journal of Cancer Care 04/2012; 21(5):623-33. DOI:10.1111/j.1365-2354.2012.01347.x · 1.56 Impact Factor
Available from: ncbi.nlm.nih.gov
- "This finding might imply (despite small absolute figures) procedural, conceptual, and definitional differences of palliative care between oncology and palliative care institutions; a “palliative patient” in the PCU seems to differ from a “palliative patient” in oncology institutions. On the other hand, conscientiously differentiating which patient might still qualify for ACT might also reflect a feature of “individualized care” : “Anticancer therapy should be discussed and offered when evidence supports a reasonable chance of providing meaningful clinical benefit.” Therefore, these results also underline the need for interdisciplinary collaboration. "
[Show abstract] [Hide abstract]
ABSTRACT: Anticancer therapies gain increasing attention and discussion in specialized palliative care institutions. Frequency, indication, attitude of team members, and modes of these therapies implemented in specialized palliative care settings are still under investigation.
Descriptive analysis of the nationwide Hospice and Palliative Care Evaluation 2007 that collected data from palliative medicine, hospice care, and oncology institutions concerning the use of anticancer therapies.
Three thousand one hundred eighty-four patients from 67 palliative care units, eight oncology wards, and other in- and outpatient institutions were registered. Two hundred eleven therapeutic interventions, mostly i.v. chemotherapy (28.9%), have been documented in all institutions except from inpatient hospices. Although all institutions were asked to keep records from "palliative patients", those patients treated in oncology services differed from patients on palliative care units with respect to prognosis, therapeutic intention (symptom control versus tumor remission), and team attitude.
Anticancer therapies are incorporated into palliative care concepts. The described differences in palliative patients that are treated in specialized palliative care as compared to oncology services will have to be discussed with regard to selection of patients for specialized palliative care and the range of suitable treatment modalities in palliative care concepts.
Supportive Care in Cancer 12/2011; 20(10):2385-9. DOI:10.1007/s00520-011-1349-8 · 2.36 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.